James van Geelen, founder of Citrini Research, is focused on the next stage of AI, surrounding humanoid robots.

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.